NANOVIRICIDES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
NANOVIRICIDES, INC. (NNVC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $0 for the 12-month period ending 2020-06-30, per its 10-K filed 2021-10-12.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2021-10-12
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2020-06-30 was -$2.07M.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2020-03-31 was $2.07M.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2019-12-31 was $0.00.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for the quarter ending 2019-09-30 was $0.00.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2020 was $0.00.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- NANOVIRICIDES, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2017 was $5.86M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|---|---|---|
| 2020-06-30 | -$2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-12 | $0.00 derived: sum of 2 quarters · filed 2021-10-12 | $0.00 derived: sum of 3 quarters · filed 2021-10-12 | $0.00 10-K · filed 2021-10-12 |
| 2020-03-31 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-22 | $2.07M derived: sum of 2 quarters · filed 2020-06-22 | $2.07M 10-Q · filed 2020-06-22 | |
| 2019-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-14 | $0.00 10-Q · filed 2020-02-14 | ||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-15 | |||
| 2018-06-30 | $0.00 10-K · filed 2020-10-13 | |||
| 2017-12-31 | $5.86M 10-Q · filed 2018-02-20 | |||
| 2017-06-30 | $5.86M 10-K · filed 2020-10-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |